Cargando…

Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes

BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, S I, Cho, S-H, Lee, J S, Moon, H-G, Noh, W C, Youn, H J, Ko, B K, Park, B-W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778309/
https://www.ncbi.nlm.nih.gov/pubmed/23942073
http://dx.doi.org/10.1038/bjc.2013.465
_version_ 1782285093675466752
author Kim, S I
Cho, S-H
Lee, J S
Moon, H-G
Noh, W C
Youn, H J
Ko, B K
Park, B-W
author_facet Kim, S I
Cho, S-H
Lee, J S
Moon, H-G
Noh, W C
Youn, H J
Ko, B K
Park, B-W
author_sort Kim, S I
collection PubMed
description BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates for post-mastectomy radiation therapy (PMRT). METHODS: Using information from 7741 node-positive patients, we first identified cutoff values of the LNR using the nonparametric bootstrap method. Focusing on 3477 patients with pN1 disease, we then evaluated the clinical relevance of the LNR categorised by the estimated cutoff values (categorised LNR, cLNR). RESULTS: Among 3477 patients with pN1 disease, 3059 and 418 patients were assigned into the low and intermediate cLNR groups, respectively, based on a cutoff value of 0.18. The prognostic factors associated with poor overall survival (OS) included younger age, T2 stage, negative oestrogen/progesterone receptors, high histologic grade, and intermediate cLNR. Post-mastectomy radiation therapy significantly increased OS in patients assigned to the intermediate cLNR (hazard ratio, 0.39; 95% confidence interval, 0.17–0.89; P=0.0248), whereas patients in the low cLNR group derived no additional survival benefit from PMRT. CONCLUSION: This study suggests that PMRT should be recommended for patients with pN1 disease and an intermediate cLNR.
format Online
Article
Text
id pubmed-3778309
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-37783092013-09-23 Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes Kim, S I Cho, S-H Lee, J S Moon, H-G Noh, W C Youn, H J Ko, B K Park, B-W Br J Cancer Clinical Study BACKGROUND: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might discriminate patients with a higher risk as candidates for post-mastectomy radiation therapy (PMRT). METHODS: Using information from 7741 node-positive patients, we first identified cutoff values of the LNR using the nonparametric bootstrap method. Focusing on 3477 patients with pN1 disease, we then evaluated the clinical relevance of the LNR categorised by the estimated cutoff values (categorised LNR, cLNR). RESULTS: Among 3477 patients with pN1 disease, 3059 and 418 patients were assigned into the low and intermediate cLNR groups, respectively, based on a cutoff value of 0.18. The prognostic factors associated with poor overall survival (OS) included younger age, T2 stage, negative oestrogen/progesterone receptors, high histologic grade, and intermediate cLNR. Post-mastectomy radiation therapy significantly increased OS in patients assigned to the intermediate cLNR (hazard ratio, 0.39; 95% confidence interval, 0.17–0.89; P=0.0248), whereas patients in the low cLNR group derived no additional survival benefit from PMRT. CONCLUSION: This study suggests that PMRT should be recommended for patients with pN1 disease and an intermediate cLNR. Nature Publishing Group 2013-09-03 2013-08-13 /pmc/articles/PMC3778309/ /pubmed/23942073 http://dx.doi.org/10.1038/bjc.2013.465 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Kim, S I
Cho, S-H
Lee, J S
Moon, H-G
Noh, W C
Youn, H J
Ko, B K
Park, B-W
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title_full Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title_fullStr Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title_full_unstemmed Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title_short Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
title_sort clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778309/
https://www.ncbi.nlm.nih.gov/pubmed/23942073
http://dx.doi.org/10.1038/bjc.2013.465
work_keys_str_mv AT kimsi clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT chosh clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT leejs clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT moonhg clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT nohwc clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT younhj clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT kobk clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes
AT parkbw clinicalrelevanceoflymphnoderatioinbreastcancerpatientswithonetothreepositivelymphnodes